These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 483251)

  • 21. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase-induced fibrin clot lysis and its inhibition by plasma.
    Carlin G
    Ups J Med Sci; 1980; 85(1):29-33. PubMed ID: 6446181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of vitreous clot lysis by urokinase: mode of action.
    Forrester JV; Edgar W; Millar W; Prentice CR; Williamson J
    Exp Eye Res; 1982 Jun; 34(6):895-907. PubMed ID: 6211365
    [No Abstract]   [Full Text] [Related]  

  • 25. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
    Terres W; Beythien C; Kupper W; Bleifeld W
    Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 29. The inhibitory effect of plasma inhibitor on plasmin activated with streptokinase or urokinase.
    Sumi H; Takada Y; Takada A
    Nihon Seirigaku Zasshi; 1977; 39(5):112-4. PubMed ID: 72149
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of the function of coagulation, fibrinolysis and pulmonary vascular endothelium before and after experimental pulmonary thromboembolism in rabbits].
    Pang BS; Wang C; Luo Q; Zhang LM; Zhu M; Mao YL; Huang XX; Guo WJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jun; 27(6):381-4. PubMed ID: 15256085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immobilization of plasminogen activator, urokinase, on nylon.
    Sugitachi A; Takagi K; Imaoka S; Kosaki G
    Thromb Haemost; 1978 Apr; 39(2):426-36. PubMed ID: 580991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase.
    Moroz LA; Sniderman AD; Marpole DG
    N Engl J Med; 1979 Nov; 301(20):1100-4. PubMed ID: 158709
    [No Abstract]   [Full Text] [Related]  

  • 35. [Studies on coagulation and fibrinolysis. III. Urokinase activated fibrinolysodynamicogram].
    Hu YM; Xue H; Wang KQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Jun; 4(3):133-6. PubMed ID: 6215134
    [No Abstract]   [Full Text] [Related]  

  • 36. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 38. Vasodilation due to urokinase in the canine femoral circulation.
    Gurll NJ; Zinner MJ; Callahan W; Reynolds DG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):731-7. PubMed ID: 864605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [State of the thrombin-plasmin system in nephrotoxic nephritis treated with heparin, urokinase, and uroplasmin].
    Monastyrskiĭ VA; Ambarova LI
    Arkh Patol; 1980; 42(1):17-22. PubMed ID: 6445726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heparin and urokinase interactions in the fibrinolytic system].
    Villaverde CA; Badimón L; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):268-9. PubMed ID: 397804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.